ArticleKidney & blood pressure research2026
Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.
Article in Kidney & blood pressure research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKidney transplant recipients (KTRs) suffer from enhanced cardiovascular (CV) and metabolic burden due to interplay between pro-inflammatory and metabolic risk factors. Nardilysin (NRDc) and mitochondrial open reading frame of 12S rRNA-c (MOTS-c) are circulating peptides that represent candidate markers of cardiometabolic pathobiology, though their relevance in KTRs is unknown.
methodsWe measured serum NRDc and MOTS-c concentrations in an observational cohort of 150 patients (118 KTRs and aged-matched controls - 32 patients) using commercial ELISA kits. KTRs were followed for a median of 29.2 (25.3-31.9) months. Relationships with CV and metabolic parameters were assessed using Pearson's correlation and penalized logistic regression. Renal allograft loss with all-cause mortality as competing event was examined using Fine-Gray regression.
resultsMedian serum NRDc (1.91 vs. 0.42 ng/mL, p < 0.001) and MOTS-c (178 vs. 142 ng/mL, p = 0.014) were significantly higher in KTRs, as compared with controls. NRDc showed a weak positive linear relationship with BMI (r = 0.21, p = 0.02). After adjusting for age and sex, higher standardized ln-NRDc was independently associated with lower odds of prevalent CV disease (OR 0.59, 95% CI: 0.34-0.97, p = 0.04). This CV disease association was stable after further adjustment for hsIL-6. We did not observe significant associations for MOTS-c and cardiometabolic features. In competing risk analysis, MOTS-c showed a consistent but nonsignificant trend toward lower risk of allograft loss (adj. sHR 0.50, 95% CI: 0.22-1.10, p = 0.08), while NRDc was not associated with allograft loss. Both serum NRDc and MOTS-c markers were not associated with all-cause mortality or follow-up eGFR decline.
conclusionsElevated circulating serum NRDc and MOTS-c levels in KTRs may reflect altered metabolic and inflammatory pathways. The inverse association between NRDc and prevalent CV disease warrants further investigation in longitudinal studies with incident CV events.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.